

<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="https://www.w3.org/1999/xlink">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Avicenna J Med Biotech</journal-id>
      <journal-id journal-id-type="publisher-id">arij002</journal-id>
      <journal-title-group>
        <journal-title>Avicenna Journal of Medical Biotechnology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2008-2835</issn>
      <issn pub-type="epub">2008-4625</issn>
      <publisher>
        <publisher-name>Avicenna Research Institute</publisher-name>
      </publisher>
    </journal-meta>

    <article-meta>
      <article-id pub-id-type="publisher-id">ajmb254</article-id>
      <article-id pub-id-type="doi"></article-id>
      <article-id pub-id-type="pmid"></article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
             <subject></subject> 
        </subj-group>
        <subj-group>
            <subject></subject>
        </subj-group> 
      </article-categories>
      <title-group>
        <article-title>Cloning and Expression of Soluble Recombinant HIV-1 CRF35 Protease-HP Thioredoxin Fusion Protein</article-title>
      </title-group>
        <contrib-group><contrib contrib-type="author"><name><surname>Azarnezhad</surname><given-names>Asaad</given-names></name></contrib><aff>Department of Pharmaceutical Biotechnology and Isfahan Pharmaceutical Research Center, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Sharifi</surname><given-names>Zohreh</given-names></name></contrib><aff>Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Seyedabadi</surname><given-names>Rahmatollah</given-names></name></contrib><aff>Recombinant Lab, Department of Biochemistry, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Hosseini</surname><given-names>Arshad</given-names></name></contrib><aff>Recombinant Lab, Department of Biochemistry, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Johari</surname><given-names>Behrooz</given-names></name></contrib><aff>Dentofacial Deformities Research Center, Research Institute of Dental Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Sobhani Fard</surname><given-names>Mahsa</given-names></name></contrib><aff>Genetic Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran</aff></contrib-group>
      <pub-date pub-type="ppub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <pub-date pub-type="epub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <volume>8</volume>
      <issue>4</issue>
      <fpage>175</fpage>
      <lpage>181</lpage>
      <history>
        <date date-type="received">
          <day>18</day>
          <month>1</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>6</day>
          <month>4</month>
          <year>2016</year>
        </date>
      </history>
      <abstract>
      <p>
      &lt;p&gt;Background: As a drug target and an antigenic agent, HIV-1 protease (HIV-1 PR) is at the center of attention for designing anti-AIDS inhibitors and diagnostic tests. In previous studies, the production of the recombinant protease has been faced with several difficulties; therefore, the aims of this study were the easy production, purification of the soluble form of protease in &lt;em&gt;E. coli&lt;/em&gt; and investigation of its immunoreactivity.&lt;br /&gt;
Methods: Protease coding region was isolated from the serum of an infected individual, amplified by RT-PCR and cloned into PTZ57R using TA-cloning. Protease coding frame was isolated by PCR and cloned in pET102/D. TOPO expression vector and cloned protease was expressed in &lt;em&gt;Escherichia coli (E. coli)&lt;/em&gt; BL21. Produced recombinant protein was purified by affinity Ni-NTA column and protein concentration was checked by BCA protein assay kit. Subsequently, immunoreactivity of recombinant protease (rPR) was assayed by Western blotting and ELISA.&lt;br /&gt;
Results: Cloning of the HIV protease by TOPO cloning system in pET102/D.TOPO was confirmed with PCR and sequencing. The concentration range of purified recombinant protein was 85 to 100&lt;em&gt; &amp;mu;g/ml&lt;/em&gt;. Immunogenicity of rPR was confirmed by Western blotting and ELISA.&lt;br /&gt;
Conclusion: Soluble production of recombinant HIV-1 protease (HIV-1 rPR) was performed successfully. This recombinant protein disclosed 86% specificity and 90% sensitivity in immunoassay tests.&lt;/p&gt;

      </p>
      </abstract>
    </article-meta>
  </front>
    
</article>
